Bionomics Limited

Established in 1996 and headquartered in Eastwood, Australia, Bionomics Limited operates as a clinical-stage biopharmaceutical firm. The company's mission is to identify and advance innovative drug treatments, primarily focusing on central nervous system (CNS) conditions and various forms of cancer. Its key experimental therapeutic, BNC210, is a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor, currently undergoing Phase 2 trials for social anxiety disorder and more advanced Phase 2b trials for post-traumatic stress disorder (PTSD). Bionomics' pipeline also includes BNC101, a monoclonal antibody designed to specifically target cancer stem cells, which has successfully completed its Phase 1 clinical evaluation. Furthermore, BNC105 is advancing through Phase 2 trials for refractory colorectal cancer and Phase 1 trials for individuals with relapsed or refractory chronic lymphocytic leukemia.